GTx, Inc.-Product Pipeline Review-2015

GTx, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07287CDB
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

GTx, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'GTx, Inc.-Product Pipeline Review-2015', provides an overview of the GTx, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GTx, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of GTx, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of GTx, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the GTx, Inc.'s pipeline products

Reasons To Buy

Evaluate GTx, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of GTx, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the GTx, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of GTx, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of GTx, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of GTx, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

GTx, Inc. Snapshot 5

GTx, Inc. Overview 5

Key Information 5

Key Facts 5

GTx, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

GTx, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

GTx, Inc.-Pipeline Products Glance 11

GTx, Inc.-Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

GTx, Inc.-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

GTx, Inc.-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

GTx, Inc.-Drug Profiles 15

enobosarm 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

GTx-758 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Beta-LGND2 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Gtx-186 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Gtx-230 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule to Inhibit Tubulin for Cancer 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

GTx, Inc.-Pipeline Analysis 26

GTx, Inc.-Pipeline Products by Target 26

GTx, Inc.-Pipeline Products by Route of Administration 27

GTx, Inc.-Pipeline Products by Molecule Type 28

GTx, Inc.-Pipeline Products by Mechanism of Action 29

GTx, Inc.-Recent Pipeline Updates 30

GTx, Inc.-Dormant Projects 38

GTx, Inc.-Discontinued Pipeline Products 39

Discontinued Pipeline Product Profiles 39

toremifene citrate 39

GTx, Inc.-Company Statement 40

GTx, Inc.-Locations And Subsidiaries 44

Head Office 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

GTx, Inc., Key Information 5

GTx, Inc., Key Facts 5

GTx, Inc.-Pipeline by Indication, 2015 8

GTx, Inc.-Pipeline by Stage of Development, 2015 9

GTx, Inc.-Monotherapy Products in Pipeline, 2015 10

GTx, Inc.-Phase III, 2015 11

GTx, Inc.-Phase II, 2015 12

GTx, Inc.-Preclinical, 2015 13

GTx, Inc.-Discovery, 2015 14

GTx, Inc.-Pipeline by Target, 2015 26

GTx, Inc.-Pipeline by Route of Administration, 2015 27

GTx, Inc.-Pipeline by Molecule Type, 2015 28

GTx, Inc.-Pipeline Products by Mechanism of Action, 2015 29

GTx, Inc.-Recent Pipeline Updates, 2015 30

GTx, Inc.-Dormant Developmental Projects,2015 38

GTx, Inc.-Discontinued Pipeline Products, 2015 39

List of Figures

GTx, Inc.-Pipeline by Top 10 Indication, 2015 7

GTx, Inc.-Pipeline by Stage of Development, 2015 9

GTx, Inc.-Monotherapy Products in Pipeline, 2015 10

GTx, Inc.-Pipeline by Top 10 Target, 2015 26

GTx, Inc.-Pipeline by Top 10 Route of Administration, 2015 27

GTx, Inc.-Pipeline by Top 10 Molecule Type, 2015 28

GTx, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of GTx, Inc.; GTx, Inc. - Key Therapeutics; GTx, Inc. - Pipeline Overview and Promising Molecules; GTx, Inc. - News; GTx, Inc. - Latest Updates; GTx, Inc. - Pipeline; GTx, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 95760
Site License
USD 3000 INR 191520
Corporate User License
USD 4500 INR 287280



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]